Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neoven is a phytotherapeutic pharmaceutical product containing 225 mg of *Ruscus aculeatus* (Butcher's Broom) extract per capsule. The extract is standardized for steroidal saponins, specifically **ruscogenin** and **neoruscogenin**, which are the primary active constituents responsible for its therapeutic effects. Neoven is primarily indicated for the treatment of **hemorrhoidal disease** (specifically stages II and III) and **chronic venous insufficiency**. It acts as a venotonic and vasoconstrictor agent, enhancing venous tone and reducing capillary permeability and filtration. Additionally, the drug exhibits anti-inflammatory and diuretic properties, which help to alleviate symptoms such as rectal bleeding, anal discomfort, itching, and edema. By improving the structural integrity of vascular cushions and reducing venous distension, Neoven serves as a non-surgical management option for symptomatic hemorrhoids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neoven.